Home › Squamous Cell Carcinoma ng Ulo at Leeg
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg na nagre-recruit sa U.S.
179 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX47 pag-aaral
- Los Angeles, CA42 pag-aaral
- Boston, MA40 pag-aaral
- New York City, NY39 pag-aaral
- Nashville, TN39 pag-aaral
- St. Louis, MO28 pag-aaral
- Philadelphia, PA26 pag-aaral
- Arlington, VA26 pag-aaral
- Chicago, IL25 pag-aaral
- Atlanta, GA23 pag-aaral
- New Haven, CT22 pag-aaral
- San Antonio, TX22 pag-aaral
- Pittsburgh, PA22 pag-aaral
- Dallas, TX20 pag-aaral
- Queens, NY20 pag-aaral
- Portland, OR19 pag-aaral
- Columbus, OH19 pag-aaral
- Cleveland, OH18 pag-aaral
- Durham, NC17 pag-aaral
- Orlando, FL16 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Miami, FL15 pag-aaral
- Tampa, FL15 pag-aaral
- Grand Rapids, MI15 pag-aaral
- Baltimore, MD15 pag-aaral
- Detroit, MI15 pag-aaral
- Edison, NJ15 pag-aaral
- Charleston, SC14 pag-aaral
- San Diego, CA14 pag-aaral
- Cincinnati, OH14 pag-aaral
- Oklahoma City, OK13 pag-aaral
- Santa Monica, CA13 pag-aaral
- Milwaukee, WI13 pag-aaral
- Omaha, NE13 pag-aaral
- Jacksonville, FL12 pag-aaral
- Louisville, KY12 pag-aaral
- Richmond, VA12 pag-aaral
- Cedar Rapids, IA12 pag-aaral
- Washington, DC11 pag-aaral
- Salt Lake City, UT11 pag-aaral
Ayos sa estado
- Alabama7 pag-aaral
- Arizona18 pag-aaral
- Arkansas10 pag-aaral
- California72 pag-aaral
- Colorado23 pag-aaral
- Connecticut24 pag-aaral
- District of Columbia9 pag-aaral
- Florida54 pag-aaral
- Georgia25 pag-aaral
- Idaho4 pag-aaral
- Illinois29 pag-aaral
- Indiana13 pag-aaral
- Iowa14 pag-aaral
- Kansas9 pag-aaral
- Kentucky17 pag-aaral
- Louisiana6 pag-aaral
- Maryland18 pag-aaral
- Massachusetts42 pag-aaral
- Michigan35 pag-aaral
- Minnesota23 pag-aaral
- Missouri29 pag-aaral
- Montana5 pag-aaral
- Nebraska15 pag-aaral
- Nevada4 pag-aaral
- New Hampshire3 pag-aaral
- New Jersey26 pag-aaral
- New Mexico3 pag-aaral
- New York54 pag-aaral
- North Carolina27 pag-aaral
- North Dakota6 pag-aaral
- Ohio46 pag-aaral
- Oklahoma14 pag-aaral
- Oregon19 pag-aaral
- Pennsylvania41 pag-aaral
- Rhode Island7 pag-aaral
- South Carolina21 pag-aaral
- South Dakota9 pag-aaral
- Tennessee43 pag-aaral
- Texas69 pag-aaral
- Utah21 pag-aaral
- Vermont3 pag-aaral
- Virginia42 pag-aaral
- Washington18 pag-aaral
- Wisconsin15 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07085091Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06589804A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07814248177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07189871A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07744126Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07360314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05877599A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06385080Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06980038BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05136196A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 1
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07219212JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Nagre-recruitPhase 3
Edad 60 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04892173A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07229313Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06047379Intratumoral N17350 in Advanced Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07339176Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05983432Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06736379A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT07730021Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05267626Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06161545A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07109726Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Nagre-recruitPhase 2
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT05952934ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05059444Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.